Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Live-Attenuated RSV Vaccine (SP0125) in Infants
NCT04491877Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Live Attenuated Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of SP0125 in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Started Sep 2020; status: completed.
02
Drugs
SP0125
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04491877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491877.